Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug Development

RegulatoryAC-101 tabletsPositive

AI Analysis

Summary

Accro Bioscience announced that AC-101 tablets have been included in the NMPA CDE's Caring Plan-Extension Pilot Program, a regulatory pathway designed to encourage innovative rare disease drug development in China.

Outcome Details

Inclusion in NMPA CDE's Caring Plan-Extension Pilot Program for Rare Disease Drug Development

Importance:6/10

Sentiment:

0.60

rare diseaseChinaregulatory pathwayNMPAdrug development

Related Companies

$BHIC $CHHE

Read the original article

Published by PR Newswire Biotech on September 14, 2026 2:00 AM

Read Original